• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    2/13/23 5:13:31 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    SC 13G/A 1 s61001038.htm SCHEDULE 13G/A, AMENDMENT #1

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*


    Celularity Inc.
    (Name of Issuer)

    Class A Common Stock
    (Title of Class of Securities)

    151190105
    (CUSIP Number)


    December 31, 2022
    (Date of Event which Requires Filing
    of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [   ]     Rule 13d-1(b)
    [X]     Rule 13d-1(c)
    [   ]     Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 151190105
    13G
    Page 2 of 9 Pages
    1
    NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     
    Starr International Investments Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ☐
    (b)  ☐
     
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Bermuda
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    15,281,389
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    15,281,389
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    15,281,389
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.54%
    12
    TYPE OF REPORTING PERSON*
     
    CO


    CUSIP No. 151190105
    13G
    Page 3 of 8 Pages
    1
    NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     
    Starr International Company, Inc.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ☐
    (b)  ☐
     
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    15,281,389
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    15,281,389
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    15,281,389
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    10.54%
    12
    TYPE OF REPORTING PERSON*
     
    HC
     
     


    EXPLANATORY NOTE:
     
    This Amendment No. 1 (“Amendment No. 1”) is filed to amend the initial statement on Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 26, 2021 (the “Original Schedule 13G” and, as amended herein, the “Schedule 13G”). This Amendment No. 1 amends and restates in its entirety, all information relating to the Reporting Persons and the Reporting Persons’ beneficial ownership of the Issuer’s securities, as previously reported in the Original Schedule 13G.

    Item 1(a)
    Name of Issuer:
       
     
    Celularity Inc. (formerly known as GX Acquisition Corp.) (the “Issuer”)
       
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
       
     
    170 Park Ave
     
    Florham Park, NJ 07932
       
       
    Item 2(a)
    Name of Person Filing:
       
     
    The information required by Item 2(a) is set forth in Row 1 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
       
     
    Starr International Investments Ltd. is a wholly-owned subsidiary of Starr Investment Company, Inc. and accordingly Starr International Company, Inc. may be deemed to beneficially own such shares disclosed in this form that are directly owned by Starr International Investments Ltd.
       
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
       
     
    Starr International Investments Ltd.
     
    19 Par-la-Ville Road
     
    Hamilton, Bermuda HM11
       
    Item 2(c)
    Citizenship:
       
     
    The information required by Item 2(c) is set forth in Row 4 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Class A Common Stock, $0.0001 par value per share (“Class A Common Stock”)
       
    Item 2(e)
    CUSIP Number:
       
     
    151190105
       
    Item 3
    Statement filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c):
       
     
    The information required by Item 3 is set forth in Row 12 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
       
     
    The Issuer’s securities reported on this Schedule 13G are comprised of 15,281,389 shares of Class A Common Stock. Such total amount of securities is unchanged from the Original Schedule 13G. This Schedule 13G is being filed to reflect that in the year 2022 the Reporting Persons exercised the 6,640,694 warrants to purchase shares of Class A Common Stock disclosed in the Original Schedule 13G and that, as of the date of this filing, all securities of the Issuer held by the Reporting Persons are comprised solely of Class A Common Stock.
       
     
    These securities are directly owned by Starr International Investments Ltd., a wholly-owned subsidiary of Starr International Company, Inc. By virtue of this relationship, Starr International Company, Inc. may be deemed to directly own such shares disclosed in this form.
       
     
    The ownership percentage disclosed in Row 11 of each cover page hereto is based on 145,013,313 outstanding shares of Class A Common Stock, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       

     Not Applicable
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    Not Applicable
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security
    Being Reported on By the Parent Holding Company or Control Person:
       
     
    See Exhibit 99.1.
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    Not Applicable
       
    Item 9
    Notice of Dissolution of Group:
       
     
    Not Applicable
       
    Item 10
    Certification:
       
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    [Remainder of page intentionally left blank]


    SIGNATURE

    After reasonable inquiry and to the best of the knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated:  February 13, 2023

     
    STARR INTERNATIONAL INVESTMENTS LTD.
       
     
    By:
    /s/ Stuart Osborne                                                     
       
    Name:  Stuart Osborne
       
    Title:  Controller and Vice President
       
       
     
    STARR INTERNATIONAL COMPANY, INC.
       
     
    By:
    /s/ Stuart Osborne                                                    
       
    Name:  Stuart Osborne
       
    Title:  President and Treasurer
    Get the next $CELU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    SEC Filings

    View All

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    8/18/25 4:30:34 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    8/12/25 4:59:59 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Celularity Inc.

    D - Celularity Inc (0001752828) (Filer)

    8/5/25 6:16:24 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

    Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet.Entered into an Asset Purchase Agreement with Celeniv Pte. Ltd., or Celeniv, to monetize Celularity intellectual property assets and eliminate senior secured debt. In connection therewith entered into a License Agreement with Celeniv to license back the intellectual property assets on an exclusive basis with an exclusive five-year repurchase option.Completed an internal restructuring and realignment to create wholly owned operating subsidiaries for its four commercial businesses—advanced

    8/18/25 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

    Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into a strategic partnership with Fountain Life, a global leader in science-backed longevity and preventative health company, to supply stem cell therapy products manufactured and distribute

    7/9/25 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

    New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management  FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians' use of investigational stem cell therapies in the state in orthopedics, wound care, and pain management. "Today, a groundbreaking new law takes effect in Florida authorizing physicians to provide stem cell therapies to their patients subject to strict requirements ensuring patien

    7/1/25 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Lim Kok Thay

    4 - Celularity Inc (0001752828) (Issuer)

    7/28/25 9:40:50 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Levien Vincent

    4 - Celularity Inc (0001752828) (Issuer)

    7/28/25 4:30:06 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dossantos Joseph

    3 - Celularity Inc (0001752828) (Issuer)

    7/16/25 8:24:27 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    1/17/24 5:22:20 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    10/10/23 9:48:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celularity downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

    1/30/23 7:11:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity downgraded by Oppenheimer

    Oppenheimer downgraded Celularity from Outperform to Perform

    12/22/22 7:40:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Celularity with a new price target

    H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

    6/22/22 7:19:25 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    Celularity Appoints Richard J. Berman to its Board of Directors

    FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol

    8/28/24 4:45:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

    FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera

    9/7/23 4:10:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Appoints Paul Graves as Chief Communications Officer

    FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C

    1/4/23 4:10:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Financials

    Live finance-specific insights

    View All

    Celularity Provides Corporate Update

    FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

    10/22/24 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    3/15/24 5:32:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    SC 13G/A - Celularity Inc (0001752828) (Subject)

    2/8/24 6:00:11 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    1/17/24 5:15:41 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care